Current ideas about molecular genetic subtypes of ovarian cancer: a personalized approach and a new platform for further research
Keywordsovarian cancer, molecular genetic heterogeneity, molecular subtypes, prognosis, reproducibility
Highly malignant ovarian cancers are a histopathological diagnosis, but can be multiple diseases at the molecular level. Research aimed at identifying molecular genetic subtypes of ovarian cancer is being conducted to find an answer to the question: can different molecular subgroups influence the choice of treatment? One of the achievements of this direction is the recognition of the dualistic theory of the origin of ovarian carcinomas with their division into High-grade and Low-grade subtypes. However, the data of sequencing of the tumor genome suggest the existence of 6 subtypes of carcinoma, including two LG and four HG subtypes. Patients of subtype C1 are characterized by a high stromal response and have the lowest survival, tumors of C2 and C4 subtypes have a higher rate of intratumoral CD3 + cells, lower stroma gene expression and better survival than C1. The mesenchymal subtype C5 is widely represented by mesenchymal cells, characterized by overexpression of N-cadherins and P-cadherins, low expression of differentiation markers and lower survival than C2 and C4. The use of a consensus algorithm to determine the subtype allows the identification of only a minority of ovarian cancers (approximately 25%). In this regard, the practical significance of this classification still requires additional research, and today it is permissible to talk about the existence of only 2-3 reproducible subtypes. It is thought that it makes sense to randomize tumors into groups with altered expression of angiogenic genes and with overexpression of immune response genes, as in the angiogenic group there is a comparison of the advantage in survival (prescribing bevacizumab improves it, and in the immune group even increases bevacizumab). Molecular subtypes with poorer survival rates (proliferative and mesenchymal) also benefit most from bevacizumab treatment. The review focuses on some advances in understanding molecular, cellular, and genetic changes related to ovarian cancers with the results achieved so far in describing molecular subtypes of ovarian cancer. The available information is the basis for planning further research.
Imyanitov IM, Hanson KP Molecular oncology: clinical aspects. - SPb .: SPbMAPO, 2007. - 211 с.
Pokataev IA, Tyulyandin SA General principles of drug therapy of female genital tumors // http: ovariancancer.ru/specialistam/generalprinciplesofchemo.htm.
Banerjee S., Kaye S.B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential // Clin. Cancer Res. — 2013. — Vol. 19 (5). — P. 961-968. doi:10.1158/1078-0432.CCR-12-2243.
Biotargets of Cancer in Current Clinical Practice / Mauro Bologna. Springer Science & Business Media, 2012. — P. 563.
Bonome T., Levine D.A., Shih J. et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer // Cancer Res. — 2008. — Vol. 68(13). — P. 5478-5486.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma // Nature. — 2011. — Vol. 474 (7353). — P. 609-615.
Chen G.M., Kannan L., Geistlinger L. et al. Consensus on Molecular Subtypes of Ovarian Cancer // bioRxiv. — 2017. — abstr. 162685. — doi: https://doi.org/10.1101/162685.
Gourley C., McCavigan A, Perren T. et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab // J. Clin. Oncol. — 2014. — Vol. 32(15). — suppl.5502. — doi: 10.1200/jco.2014.32.15_suppl.5502.
Helland Å., Anglesio M.S., George J. et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers // PLoS One. — 2011. — Vol. 6(4). — doi.org/10.1371/journal. pone.0018064.
Kommoss S., Winterhoff B., Oberg A.L. et al. Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes // Clin. Cancer Res. – 2017. — Vol. 23(14). — P. 3794-3801. — doi: 10.1158/1078-0432.CCR-16-2196.
Konecny G.E., Wang C., Hamidi H. et al. Prognostic and therapeutic relevance of molecular subtypes in highgrade serous ovarian cancer// J. Natl. Cancer Inst. — 2014. — Vol. 106(10). –doi:10.1093/jnci/dju249.
Kurman R.J., Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm // Hum. Pathol. — 2011. — Vol. 42. — P. 918–931.
Lohr J.G., Stojanov P., Carter S.L. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy // Cancer Cell. — 2014. — Vol. 25(1). — P. 91-101.
Michiels S., Rotolo F. Evaluation of clinical utility and validation of gene signatures in clinical trials. In Matsui S, Buyse M, Simon R. (eds). Design and Analysis of Clinical Trials for Predictive Medicine. Boca Raton, Florida: CRC Press, 2015. — P. 187–203.
Tothill R.W., Tinker A.V., George J. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome // Clin Cancer Res. — 2008. — Vol. 14. — P. 5198–5208. –doi: 10.1158/1078-0432. CCR-08-0196.
Verhaak R.G., Tamayo P., Yang J. et al. Cancer Genome Atlas Research Network: Prognostically relevant gene signatures of highgrade serous ovarian carcinoma // J. Clin. Invest. — 2013. — Vol. 123. — P. 517-525.
Way G.P., Rudd J., Wang C. et al. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. G3 (Bethesda). — 2016. — Vol. 6(12). — P. 4097-4103. – doi: 10.1534/g3.116.033514.
Winterhoff B., Kommoss S., Oberg A.L. et al. Bevacizumab may differentially improve survival for patients with the proliferative and mesenchymal molecular subtype of ovarian cancer // Journal of Clinical Oncology. – 2014. — Vol. 32(15). — suppl. — P. 5509-5509. — doi: 10.1158/1078-0432.CCR-16-2196.
How to Cite
Copyright (c) 2021 A. Rybin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.The periodical offers access to content in the Open Access system under the Creative Commons non-exclusive license (CC BY-ND 4.0).
Number of views and downloads: 30
Number of citations: 0